Cenerimod for Active Lupus Nephritis
Part of Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This trial tests if an investigational drug called cenerimod can safely and effectively treat active lupus nephritis when added to your regular lupus medications. It's for people with recent kidney biopsy showing active lupus kidney disease and high protein in urine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a lupus-related kidney problem called lupus nephritis, confirmed by a recent kidney biopsy showing class III, IV, or pure class V.
- You have high protein levels in your urine, a sign of active kidney disease.
- Your kidney function is at least 15% of normal (eGFR of 15 or higher), and if it's between 15 and 30, your kidney biopsy must show limited scarring.
- You agree to take standard treatments for lupus nephritis: mycophenolate (CellCept or Myfortic) and high-dose steroids (pills and possibly IV).
- You cannot have severe lupus affecting the brain, other serious kidney diseases, certain heart rhythm problems, or active infections like tuberculosis or hepatitis.
- If you can get pregnant, you must use very effective birth control and take pregnancy tests during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests the long-term safety of a drug called cenerimod for people with lupus (SLE) who have already completed a 12-month study of the same drug. It helps researchers see if the medicine stays safe and tolerable over a longer period.
This trial tests a new medicine, nipocalimab, for adults with moderate to severe lupus. It aims to see if the drug can help control lupus symptoms and reduce disease activity.
This trial tests whether sirolimus, a medication usually used to prevent organ transplant rejection, can help reduce lupus disease activity. If you have active lupus that isn't severe in your kidneys or brain, this could be a new treatment option.
This trial tests a new kind of treatment called CRC01, which uses your own immune cells modified to attack and calm the overactive immune system that causes lupus. It's for people with severe lupus that affects the kidneys and hasn't improved with standard therapies, and it aims to reduce disease activity and prevent further damage.
This trial tests a new treatment for people with lupus nephritis, a type of kidney disease caused by lupus. It may help reduce kidney inflammation and protect kidney function.
This trial tests two biologic drugs (belimumab or telitacicept) compared to a standard treatment (mycophenolate mofetil) for people with active lupus nephritis. The goal is to see if biologics work better at controlling kidney inflammation over 6 months.
Hear when a new Lupus Erythematosus, Systemic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.